EPM editor Reece Armstrong examines the consequences of faulty data for a well-known pharma company.
The pharmaceutical industry was in for a shock this month when it was revealed that Novartis included faulty data when it applied for the regulatory approval of its contentious gene therapy, Zolgensma – oh ‘big pharma’ just when I was beginning to trust you.
Novartis was already in the spotlight over the cost of Zolgensma - which sells for $2.1 million – and now the FDA has lambasted the company, even mentioning potential ‘civil or criminal penalties.’